1. Home
  2. MFA vs AKBA Comparison

MFA vs AKBA Comparison

Compare MFA & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MFA
  • AKBA
  • Stock Information
  • Founded
  • MFA 1997
  • AKBA 2007
  • Country
  • MFA United States
  • AKBA United States
  • Employees
  • MFA N/A
  • AKBA N/A
  • Industry
  • MFA Real Estate Investment Trusts
  • AKBA Biotechnology: Pharmaceutical Preparations
  • Sector
  • MFA Real Estate
  • AKBA Health Care
  • Exchange
  • MFA Nasdaq
  • AKBA Nasdaq
  • Market Cap
  • MFA 1.1B
  • AKBA 861.7M
  • IPO Year
  • MFA N/A
  • AKBA 2014
  • Fundamental
  • Price
  • MFA $10.12
  • AKBA $2.97
  • Analyst Decision
  • MFA Buy
  • AKBA Strong Buy
  • Analyst Count
  • MFA 8
  • AKBA 5
  • Target Price
  • MFA $11.50
  • AKBA $6.90
  • AVG Volume (30 Days)
  • MFA 931.4K
  • AKBA 3.9M
  • Earning Date
  • MFA 11-05-2025
  • AKBA 11-06-2025
  • Dividend Yield
  • MFA 14.13%
  • AKBA N/A
  • EPS Growth
  • MFA 41.64
  • AKBA N/A
  • EPS
  • MFA 0.88
  • AKBA N/A
  • Revenue
  • MFA $284,489,000.00
  • AKBA $203,733,000.00
  • Revenue This Year
  • MFA N/A
  • AKBA $38.23
  • Revenue Next Year
  • MFA $16.86
  • AKBA $38.17
  • P/E Ratio
  • MFA $11.58
  • AKBA N/A
  • Revenue Growth
  • MFA 9.37
  • AKBA 16.75
  • 52 Week Low
  • MFA $7.85
  • AKBA $1.24
  • 52 Week High
  • MFA $13.45
  • AKBA $4.08
  • Technical
  • Relative Strength Index (RSI)
  • MFA 55.26
  • AKBA 40.34
  • Support Level
  • MFA $10.15
  • AKBA $2.92
  • Resistance Level
  • MFA $10.57
  • AKBA $3.15
  • Average True Range (ATR)
  • MFA 0.18
  • AKBA 0.14
  • MACD
  • MFA -0.02
  • AKBA 0.00
  • Stochastic Oscillator
  • MFA 26.73
  • AKBA 17.19

About MFA MFA Financial Inc.

MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: